Filing Flows › Comparisons › ATYR vs PROK
aTYR Pharma vs Prokidney: ATYR and PROK compared
aTYR Pharma is the larger company: $190K of revenue in its latest quarter (Q3 2025) against $150K for Prokidney (Q2 2026).
Where the money goes: ATYR and PROK
aTYR Pharma (ATYR) · Q3 2025
aTYR Pharma, Q3 2025: revenue $190K, net loss $25.7M, operating cash flow −$20.5M. The chart follows the revenue to costs, profit and cash.
Prokidney (PROK) · Q2 2026
Prokidney, Q2 2026: revenue $150K (-32% year over year), net loss $46.4M, operating cash flow −$40.4M. The chart follows the revenue to costs, profit and cash.
| aTYR Pharma (ATYR) | Prokidney (PROK) | |
|---|---|---|
| Latest quarter | Q3 2025 | Q2 2026 |
| Revenue | $190K | $150K |
| Revenue growth, Y/Y | — | -32% |
| Operating margin | n/m | n/m |
| Net earnings | −$25.7M | −$46.4M |
| Operating cash flow | −$20.5M | −$40.4M |
Questions
Which is bigger, aTYR Pharma or Prokidney?
aTYR Pharma is the larger company: $190K of revenue in its latest quarter (Q3 2025) against $150K for Prokidney (Q2 2026).
More: aTYR Pharma earnings · how aTYR Pharma makes money · Prokidney earnings · how Prokidney makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 6, 2025; 10-Q filed Aug 10, 2026). Fiscal quarters can end on different dates. Not investment advice.